Skip to main content
Top
Published in: Dermatology and Therapy 11/2023

Open Access 01-10-2023 | Pruritus | Original Research

Neurotrophin-4 and Brain-Derived Neurotrophic Factor Serum Levels in Renal Transplant Recipients with Chronic Pruritus

Authors: Kinga Tyczyńska, Piotr K. Krajewski, Danuta Nowicka-Suszko, Dariusz Janczak, Hanna Augustyniak-Bartosik, Magdalena Krajewska, Jacek C. Szepietowski

Published in: Dermatology and Therapy | Issue 11/2023

Login to get access

Abstract

Introduction

Chronic pruritus (CP) is a common symptom defined as a sensation that provokes the desire to scratch and which lasts for at least 6 weeks. CP remains a problem for up to 21.3% of renal transplant recipients (RTRs). Our research aimed to establish the possible association between serum levels of neurotrophin-4 (NT-4) and brain-derived neurotrophic factor (BDNF) and the presence and intensity of CP in RTR.

Methods

The study was performed on a group of 129 RTRs, who were divided according to the presence or absence of pruritus in the previous 3 days. The assessment of pruritus was performed with the use of a numeric rating scale (NRS), 4-Item Itch Questionnaire (4IIQ), and Itchy Quality of Life (Itchy QoL). A total of 129 blood samples with a volume of 9 ml were drawn from RTRs during the monthly routine control. Serum levels (pg/mL) of NT-4 and BDNF were measured by the ELISA.

Results

Pruritic RTRs have statistically significantly higher serum concentrations of NT-4 serum level compared to non-pruritic RTRs (229.17 ± 143.86 pg/mL and 153.08 ± 78.19 pg/mL [p = 0.024], respectively). Moreover, a statistically significant difference between pruritic and non-pruritic RTRs with healthy controls was shown (p < 0.001 and p < 0.001, respectively). Although there was a numerically higher serum concentration of BDNF in pruritic RTRs (32.18 ± 7.31 pg/mL vs. 31.58 ± 10.84 pg/mL), the difference did not reach statistical significance. No statistically significant difference was also seen in BDNF serum levels between RTRs and healthy controls. Furthermore, there was a statistically significant, positive correlation between serum concentration of NT-4 and NRS score (p = 0.008, r = 0.357).

Conclusions

The results indicate higher NT-4 serum concentration in RTRs with pruritus compared to RTRs without pruritus. Furthermore, the study revealed a statistically significant, positive correlation between the serum concentration of NT-4 and NRS score.
Literature
1.
go back to reference Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99(5):469–506.PubMedCrossRef Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99(5):469–506.PubMedCrossRef
2.
go back to reference Stander S, Schafer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology. 2010;221(3):229–35.PubMedCrossRef Stander S, Schafer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology. 2010;221(3):229–35.PubMedCrossRef
3.
go back to reference Hayani K, Weiss M, Weisshaar E. Clinical findings and provision of care in haemodialysis patients with chronic itch: new results from the German epidemiological haemodialysis itch study. Acta Derm Venereol. 2016;96(3):361–6.PubMedCrossRef Hayani K, Weiss M, Weisshaar E. Clinical findings and provision of care in haemodialysis patients with chronic itch: new results from the German epidemiological haemodialysis itch study. Acta Derm Venereol. 2016;96(3):361–6.PubMedCrossRef
4.
go back to reference Krajewski PK, Olczyk P, Krajewska M, Krajewski W, Szepietowski JC. Clinical characteristics of itch in renal transplant recipients. Front Med (Lausanne). 2020;7: 615334.PubMedCrossRef Krajewski PK, Olczyk P, Krajewska M, Krajewski W, Szepietowski JC. Clinical characteristics of itch in renal transplant recipients. Front Med (Lausanne). 2020;7: 615334.PubMedCrossRef
5.
go back to reference Stahle-Backdahl M, Hagermark O, Lins LE, Torring O, Hilliges M, Johansson O. Experimental and immunohistochemical studies on the possible role of parathyroid hormone in uraemic pruritus. J Intern Med. 1989;225(6):411–5.PubMedCrossRef Stahle-Backdahl M, Hagermark O, Lins LE, Torring O, Hilliges M, Johansson O. Experimental and immunohistochemical studies on the possible role of parathyroid hormone in uraemic pruritus. J Intern Med. 1989;225(6):411–5.PubMedCrossRef
6.
go back to reference Gill DS, Fonseca VA, Barradas MA, Balliod R, Moorhead JF, Dandona P. Plasma histamine in patients with chronic renal failure and nephrotic syndrome. J Clin Pathol. 1991;44(3):243–5.PubMedPubMedCentralCrossRef Gill DS, Fonseca VA, Barradas MA, Balliod R, Moorhead JF, Dandona P. Plasma histamine in patients with chronic renal failure and nephrotic syndrome. J Clin Pathol. 1991;44(3):243–5.PubMedPubMedCentralCrossRef
7.
go back to reference Dugas-Breit S, Schopf P, Dugas M, Schiffl H, Rueff F, Przybilla B. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. J Dtsch Dermatol Ges. 2005;3(5):343–7.PubMedCrossRef Dugas-Breit S, Schopf P, Dugas M, Schiffl H, Rueff F, Przybilla B. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. J Dtsch Dermatol Ges. 2005;3(5):343–7.PubMedCrossRef
8.
go back to reference Duque MI, Thevarajah S, Chan YH, Tuttle AB, Freedman BI, Yosipovitch G. Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clin Nephrol. 2006;66(3):184–91.PubMedCrossRef Duque MI, Thevarajah S, Chan YH, Tuttle AB, Freedman BI, Yosipovitch G. Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clin Nephrol. 2006;66(3):184–91.PubMedCrossRef
9.
go back to reference Kimmel M, Alscher DM, Dunst R, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant. 2006;21(3):749–55.PubMedCrossRef Kimmel M, Alscher DM, Dunst R, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant. 2006;21(3):749–55.PubMedCrossRef
10.
go back to reference Blachley JD, Blankenship DM, Menter A, Parker TF 3rd, Knochel JP. Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. Am J Kidney Dis. 1985;5(5):237–41.PubMedCrossRef Blachley JD, Blankenship DM, Menter A, Parker TF 3rd, Knochel JP. Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. Am J Kidney Dis. 1985;5(5):237–41.PubMedCrossRef
11.
go back to reference Reszke R, Kilis-Pstrusinska K, Szepietowski JC. Chronic kidney disease-associated itch (CKD-aI) in children—a narrative review. Toxins (Basel). 2021;13(7):450.PubMedCrossRef Reszke R, Kilis-Pstrusinska K, Szepietowski JC. Chronic kidney disease-associated itch (CKD-aI) in children—a narrative review. Toxins (Basel). 2021;13(7):450.PubMedCrossRef
12.
go back to reference Wala-Zielinska K, Swierczynska-Mroz K, Krajewski PK, Nowicka-Suszko D, Krajewska M, Szepietowski JC. Elevated level of serum neurotrophin-4, but not of brain-derived neurotrophic factor, in patients with chronic kidney disease-associated pruritus. J Clin Med. 2022;11(21):6292.PubMedPubMedCentralCrossRef Wala-Zielinska K, Swierczynska-Mroz K, Krajewski PK, Nowicka-Suszko D, Krajewska M, Szepietowski JC. Elevated level of serum neurotrophin-4, but not of brain-derived neurotrophic factor, in patients with chronic kidney disease-associated pruritus. J Clin Med. 2022;11(21):6292.PubMedPubMedCentralCrossRef
13.
go back to reference Swierczynska K, Krajewski PK, Nowicka-Suszko D, Bialynicki-Birula R, Krajewska M, Szepietowski JC. The serum level of IL-31 in patients with chronic kidney disease-associated pruritus: what can we expect? Toxins (Basel). 2022;14(3):197.PubMedCrossRef Swierczynska K, Krajewski PK, Nowicka-Suszko D, Bialynicki-Birula R, Krajewska M, Szepietowski JC. The serum level of IL-31 in patients with chronic kidney disease-associated pruritus: what can we expect? Toxins (Basel). 2022;14(3):197.PubMedCrossRef
14.
go back to reference Wala-Zielinska K, Swierczynska-Mroz K, Krajewski PK, Nowicka-Suszko D, Krajewska M, Szepietowski JC. Endogenous opioid imbalance as a potential factor involved in the pathogenesis of chronic kidney disease-associated pruritus in dialysis patients. J Clin Med. 2023;12(7):2474.PubMedPubMedCentralCrossRef Wala-Zielinska K, Swierczynska-Mroz K, Krajewski PK, Nowicka-Suszko D, Krajewska M, Szepietowski JC. Endogenous opioid imbalance as a potential factor involved in the pathogenesis of chronic kidney disease-associated pruritus in dialysis patients. J Clin Med. 2023;12(7):2474.PubMedPubMedCentralCrossRef
15.
go back to reference Krajewski PK, Tyczynska K, Bardowska K, Olczyk P, Krajewska M, Szepietowski JC. Psychosocial burden of itch among renal transplant recipients. Toxins (Basel). 2022;14(5):320.PubMedCrossRef Krajewski PK, Tyczynska K, Bardowska K, Olczyk P, Krajewska M, Szepietowski JC. Psychosocial burden of itch among renal transplant recipients. Toxins (Basel). 2022;14(5):320.PubMedCrossRef
16.
go back to reference Te-Linde E, van Roij CJM, Meijers BKI, De Loor H, Kessels RPC, Wetzels JFM. Cognitive function and uremic toxins after kidney transplantation: an exploratory study. Kidney 360. 2020;1(12):1398–406.PubMedPubMedCentralCrossRef Te-Linde E, van Roij CJM, Meijers BKI, De Loor H, Kessels RPC, Wetzels JFM. Cognitive function and uremic toxins after kidney transplantation: an exploratory study. Kidney 360. 2020;1(12):1398–406.PubMedPubMedCentralCrossRef
17.
go back to reference Krajewski PK, Tyczynska K, Bardowska K, et al. High serum IL-31 concentration is associated with itch among renal transplant recipients. J Clin Med. 2022;11(15):4309.PubMedPubMedCentralCrossRef Krajewski PK, Tyczynska K, Bardowska K, et al. High serum IL-31 concentration is associated with itch among renal transplant recipients. J Clin Med. 2022;11(15):4309.PubMedPubMedCentralCrossRef
18.
go back to reference Reich A, Chatzigeorkidis E, Zeidler C, et al. Tailoring the cut-off values of the visual analogue scale and numeric rating scale in itch assessment. Acta Derm Venereol. 2017;97(6):759–60.PubMedCrossRef Reich A, Chatzigeorkidis E, Zeidler C, et al. Tailoring the cut-off values of the visual analogue scale and numeric rating scale in itch assessment. Acta Derm Venereol. 2017;97(6):759–60.PubMedCrossRef
19.
go back to reference Reich A, Mędrek K, Szepietowski J. Czteropunktowy kwestionariusz oceny świądu – walidacja kwestionariusza. Dermatol Rev/Przegląd Dermatologiczny. 2012;99(5):600–4. Reich A, Mędrek K, Szepietowski J. Czteropunktowy kwestionariusz oceny świądu – walidacja kwestionariusza. Dermatol Rev/Przegląd Dermatologiczny. 2012;99(5):600–4.
20.
go back to reference Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol. 2008;59(2):234–44.PubMedCrossRef Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol. 2008;59(2):234–44.PubMedCrossRef
24.
go back to reference Timmusk T, Belluardo N, Metsis M, Persson H. Widespread and developmentally regulated expression of neurotrophin-4 mRNA in rat brain and peripheral tissues. Eur J Neurosci. 1993;5(6):605–13.PubMedCrossRef Timmusk T, Belluardo N, Metsis M, Persson H. Widespread and developmentally regulated expression of neurotrophin-4 mRNA in rat brain and peripheral tissues. Eur J Neurosci. 1993;5(6):605–13.PubMedCrossRef
25.
go back to reference Ibanez CF. Neurotrophin-4: the odd one out in the neurotrophin family. Neurochem Res. 1996;21(7):787–93.PubMedCrossRef Ibanez CF. Neurotrophin-4: the odd one out in the neurotrophin family. Neurochem Res. 1996;21(7):787–93.PubMedCrossRef
26.
go back to reference Brady ST, Siegel GJ, Albers RW, Price DL, Benjamins J. Basic neurochemistry: principles of molecular, cellular and medical neurobiology. 8th ed. Amsterdam: Elsevier/Academic; 2012. Brady ST, Siegel GJ, Albers RW, Price DL, Benjamins J. Basic neurochemistry: principles of molecular, cellular and medical neurobiology. 8th ed. Amsterdam: Elsevier/Academic; 2012.
27.
go back to reference Damiani G, Kridin K, Pacifico A, et al. Antihistamines-refractory chronic pruritus in psoriatic patients undergoing biologics: aprepitant vs antihistamine double dosage, a real-world data. J Dermatol Treat. 2022;33(3):1554–7.CrossRef Damiani G, Kridin K, Pacifico A, et al. Antihistamines-refractory chronic pruritus in psoriatic patients undergoing biologics: aprepitant vs antihistamine double dosage, a real-world data. J Dermatol Treat. 2022;33(3):1554–7.CrossRef
28.
go back to reference Grewe M, Vogelsang K, Ruzicka T, Stege H, Krutmann J. Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. J Invest Dermatol. 2000;114(6):1108–12.PubMedCrossRef Grewe M, Vogelsang K, Ruzicka T, Stege H, Krutmann J. Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. J Invest Dermatol. 2000;114(6):1108–12.PubMedCrossRef
29.
go back to reference Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007;156(6):1272–7.PubMedCrossRef Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol. 2007;156(6):1272–7.PubMedCrossRef
30.
go back to reference Sorour NE, Elesawy FM, Tabl HA, Ibrahim ME, Akl EM. Evaluation of serum levels of neurotrophin 4 and brain-derived nerve growth factor in uremic pruritus patients. Clin Cosmet Investig Dermatol. 2019;12:109–14.PubMedPubMedCentralCrossRef Sorour NE, Elesawy FM, Tabl HA, Ibrahim ME, Akl EM. Evaluation of serum levels of neurotrophin 4 and brain-derived nerve growth factor in uremic pruritus patients. Clin Cosmet Investig Dermatol. 2019;12:109–14.PubMedPubMedCentralCrossRef
31.
go back to reference Raap U, Goltz C, Deneka N, et al. Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosinophil functions compared with that seen in nonatopic subjects. J Allergy Clin Immunol. 2005;115(6):1268–75.PubMedCrossRef Raap U, Goltz C, Deneka N, et al. Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosinophil functions compared with that seen in nonatopic subjects. J Allergy Clin Immunol. 2005;115(6):1268–75.PubMedCrossRef
32.
go back to reference Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance P. Br J Dermatol. 2007;157(5):922–5.PubMedCrossRef Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance P. Br J Dermatol. 2007;157(5):922–5.PubMedCrossRef
33.
go back to reference Ma L, Gao XH, Zhao LP, et al. Brain-derived neurotrophic factor gene polymorphisms and serum levels in Chinese atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2009;23(11):1277–81.PubMedCrossRef Ma L, Gao XH, Zhao LP, et al. Brain-derived neurotrophic factor gene polymorphisms and serum levels in Chinese atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2009;23(11):1277–81.PubMedCrossRef
34.
go back to reference Folster-Holst R, Papakonstantinou E, Rudrich U, et al. Childhood atopic dermatitis-brain-derived neurotrophic factor correlates with serum eosinophil cationic protein and disease severity. Allergy. 2016;71(7):1062–5.PubMedCrossRef Folster-Holst R, Papakonstantinou E, Rudrich U, et al. Childhood atopic dermatitis-brain-derived neurotrophic factor correlates with serum eosinophil cationic protein and disease severity. Allergy. 2016;71(7):1062–5.PubMedCrossRef
35.
go back to reference Rossing K, Novak N, Mommert S, et al. Brain-derived neurotrophic factor is increased in serum and skin levels of patients with chronic spontaneous urticaria. Clin Exp Allergy. 2011;41(10):1392–9.PubMedCrossRef Rossing K, Novak N, Mommert S, et al. Brain-derived neurotrophic factor is increased in serum and skin levels of patients with chronic spontaneous urticaria. Clin Exp Allergy. 2011;41(10):1392–9.PubMedCrossRef
36.
go back to reference Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol. 2003;149(4):718–30.PubMedCrossRef Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol. 2003;149(4):718–30.PubMedCrossRef
37.
go back to reference Brunoni AR, Lotufo PA, Sabbag C, Goulart AC, Santos IS, Bensenor IM. Decreased brain-derived neurotrophic factor plasma levels in psoriasis patients. Braz J Med Biol Res. 2015;48(8):711–4.PubMedPubMedCentralCrossRef Brunoni AR, Lotufo PA, Sabbag C, Goulart AC, Santos IS, Bensenor IM. Decreased brain-derived neurotrophic factor plasma levels in psoriasis patients. Braz J Med Biol Res. 2015;48(8):711–4.PubMedPubMedCentralCrossRef
38.
go back to reference Sjahrir M, Roesyanto-Mahadi ID, Effendy E. Correlation between serum brain-derived neurotrophic factor level and depression severity in psoriasis vulgaris patients. Open Access Maced J Med Sci. 2019;7(4):583–6.PubMedPubMedCentralCrossRef Sjahrir M, Roesyanto-Mahadi ID, Effendy E. Correlation between serum brain-derived neurotrophic factor level and depression severity in psoriasis vulgaris patients. Open Access Maced J Med Sci. 2019;7(4):583–6.PubMedPubMedCentralCrossRef
39.
go back to reference Li M, Armelloni S, Zennaro C, et al. BDNF repairs podocyte damage by microRNA-mediated increase of actin polymerization. J Pathol. 2015;235(5):731–44.PubMedPubMedCentralCrossRef Li M, Armelloni S, Zennaro C, et al. BDNF repairs podocyte damage by microRNA-mediated increase of actin polymerization. J Pathol. 2015;235(5):731–44.PubMedPubMedCentralCrossRef
40.
go back to reference Endlich N, Lange T, Kuhn J, et al. BDNF: mRNA expression in urine cells of patients with chronic kidney disease and its role in kidney function. J Cell Mol Med. 2018;22(11):5265–77.PubMedPubMedCentralCrossRef Endlich N, Lange T, Kuhn J, et al. BDNF: mRNA expression in urine cells of patients with chronic kidney disease and its role in kidney function. J Cell Mol Med. 2018;22(11):5265–77.PubMedPubMedCentralCrossRef
41.
42.
go back to reference Zoladz JA, Smigielski M, Majerczak J, et al. Hemodialysis decreases serum brain-derived neurotrophic factor concentration in humans. Neurochem Res. 2012;37(12):2715–24.PubMedCrossRef Zoladz JA, Smigielski M, Majerczak J, et al. Hemodialysis decreases serum brain-derived neurotrophic factor concentration in humans. Neurochem Res. 2012;37(12):2715–24.PubMedCrossRef
43.
go back to reference Fugal J, Serpa SM. Difelikefalin: a new kappa-opioid receptor agonist for the treatment of hemodialysis-dependent chronic kidney disease-associated pruritus. Ann Pharmacother. 2023;57(4):480–8.PubMedCrossRef Fugal J, Serpa SM. Difelikefalin: a new kappa-opioid receptor agonist for the treatment of hemodialysis-dependent chronic kidney disease-associated pruritus. Ann Pharmacother. 2023;57(4):480–8.PubMedCrossRef
44.
go back to reference Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542–8.PubMedCrossRef Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542–8.PubMedCrossRef
Metadata
Title
Neurotrophin-4 and Brain-Derived Neurotrophic Factor Serum Levels in Renal Transplant Recipients with Chronic Pruritus
Authors
Kinga Tyczyńska
Piotr K. Krajewski
Danuta Nowicka-Suszko
Dariusz Janczak
Hanna Augustyniak-Bartosik
Magdalena Krajewska
Jacek C. Szepietowski
Publication date
01-10-2023
Publisher
Springer Healthcare
Keyword
Pruritus
Published in
Dermatology and Therapy / Issue 11/2023
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-023-01029-4

Other articles of this Issue 11/2023

Dermatology and Therapy 11/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.